Axiom Biosciences, rebranded from Cytonus Therapeutics Inc. in June 2026, plans to be one of the first U.S. biotechs to IPO on the main board of The Stock Exchange of Hong Kong. The San Diego-based company is preparing audits as the first step to a potential IPO in 2027.
BioWorld BioWorld Asia Financings Neurology/psychiatric IPO Asia-Pacific U.S.